Saliva Analyzer for Diagnosing SRD Patient Drug Use

Information

  • Research Project
  • 8198802
  • ApplicationId
    8198802
  • Core Project Number
    R43DA032178
  • Full Project Number
    1R43DA032178-01
  • Serial Number
    032178
  • FOA Number
    PA-10-050
  • Sub Project Id
  • Project Start Date
    7/15/2012 - 12 years ago
  • Project End Date
    6/30/2013 - 11 years ago
  • Program Officer Name
    SINGH, HARI
  • Budget Start Date
    7/15/2012 - 12 years ago
  • Budget End Date
    6/30/2013 - 11 years ago
  • Fiscal Year
    2012
  • Support Year
    01
  • Suffix
  • Award Notice Date
    7/12/2012 - 12 years ago

Saliva Analyzer for Diagnosing SRD Patient Drug Use

DESCRIPTION (provided by applicant): The overall aim of this SBIR program is to develop a surface-enhanced Raman spectroscopy (SERS) based device for on-site analysis of drugs in saliva. This device will allow immediate assessment of both medicinal and illicit drug use by patients with substance-related disorders (SRDs), and provide medical professionals and management with quantitative data so that treatment decisions can be made. Successful treatments for SRD patients require frequent monitoring of both medicinal and illicit drug use, which are mostly done in outpatient settings (doctor's office, rehabilitation centers, etc.) employing urine- based drug tests. For such tests, a sample is screened with immunoassay test kits, and if a drug is present, it is confirmed and quantified by gas chromatography - mass spectrometry (GC-MS). Unfortunately, immunoassay test kits are susceptible to false positives, while the GC-MS method is time consuming and requires highly trained operators and a laboratory setting. Consequently, there is a critical need for a device that combines the portability, speed and ease-of-use of immunoassay kits with the identification and quantitation abilities of GC-MS so that health care personnel can assess SRD patient compliance in outpatient settings. The proposed SERS Saliva Analyzer (SSA) will meet all such requirements by providing health care personnel an easy-to-use device, which will extract, identify and quantify the presence of drugs (and metabolites) at requisite levels in saliva (1-50 ng/mL), within 10 minutes. The overall aim of the Phase I program is to demonstrate feasibility by detecting two priority drugs (cocaine and diazepam) in saliva at physiologically relevant concentrations and analysis time. This will be accomplished by 1) measuring cocaine and diazepam at required sensitivity, and 2) measuring cocaine and diazepam in saliva. PUBLIC HEALTH RELEVANCE: The overall aim of this SBIR program is to develop a surface-enhanced Raman spectroscopy (SERS) based device for on-site analysis of drugs in saliva. This device will allow immediate assessment of both medicinal and illicit drug use by patients with substance-related disorders (SRDs), and provide medical professionals and management with quantitative data so that treatment decisions can be made.

IC Name
NATIONAL INSTITUTE ON DRUG ABUSE
  • Activity
    R43
  • Administering IC
    DA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    156535
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    279
  • Ed Inst. Type
  • Funding ICs
    NIDA:156535\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    REAL-TIME ANALYZERS, INC.
  • Organization Department
  • Organization DUNS
    076890222
  • Organization City
    MIDDLETOWN
  • Organization State
    CT
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    064571548
  • Organization District
    UNITED STATES